MedTrace Logo

A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia

NCT01886053 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 189

Last updated 2013-06-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects，and explore its therapeutic dose.

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Faropenem（high dose group）

dosage form: Injection dosage:2400 mg frequency: Three times a day

DRUG

Faropenem（low-dose group)

dosage form: Injection dosage:2400 mg frequency: twice a day

DRUG

Ertapenem

dosage form: Injection dosage:1000 mg frequency: once a day

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01886053 on ClinicalTrials.gov